anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Clinical Trial Adverse Events. Clomiphene citrate, at recommended dosages, is generally well tolerated. Adverse reactions usually have been mild and transient and most have disappeared promptly after treatment has been discontinued. Adverse experiences reported in patients treated with clomiphene citrate during clinical studies are shown in Table 2.

The following adverse events have been reported in fewer than 1% of patients in clinical trials: Acute abdomen, appetite increase, constipation, dermatitis or rash, depression, diarrhea, dizziness, fatigue, hair loss/dry hair, increased urinary frequency/volume, insomnia, light-headedness, nervous tension, vaginal dryness, vertigo, weight gain/loss.

Patients on prolonged clomiphene citrate therapy may show elevated serum levels of desmosterol. This is most likely due to a direct interference with cholesterol synthesis. However, the serum sterols in patients receiving the recommended dose of clomiphene citrate are not significantly altered. Ovarian cancer has been infrequently reported in patients who have received fertility drugs. Infertility is a primary risk factor for ovarian cancer; however, epidemiology data suggest that prolonged use of clomiphene may increase the risk of a borderline or invasive ovarian tumor.
Intervention group parents will receive 9 intervention sessions every other week by trained staff via 9 online sessions via Zoom or phone calls. Each intervention session will last 30-40 minutes. Intervention group parents will receive 3 text messages per week. No in-person contacts will be conducted without MSU department permission. All assessments will be delivered remotely with guided phone calls or zoom conference. The assessment of dyads' BMI, %BF, and WC will be obtained remotely from the parents using the scale and measuring tape delivered to their home.
Cosmetic detergent composition, comprises: an anionic surface-active (I) sulfate/sulfonate; an anionic carboxylic surface-active different from (I) e.g. alkyl carboxylic acid polyoxyalkylene ether with 6-24 carbon; amphoteric surface-active agent; and an ester of carboxylic acid insoluble in water e.g. esters of carboxylic acid with 3-30 carbon and alcohol of 1-30 carbon, where at least one of which is branched, in an aqueous medium. The esters are present at 0.5-10 wt.%. The ratio of anionic surface-active sulfates or sulfonate/anionic carboxylic surface-active agent is 2-12. Detergent cosmetic composition, comprises: an anionic surface-active (I) sulfate or sulfonate; an anionic surface-active carboxylic different from (I) e.g. alkyl carboxylic acid polyoxyalkylene ether with 6-24 carbon, alkylaryl carboxylic acids polyalkylene ether with 6-24 and their salts, alkylamido carboxylic polyoxyalkylene ether with 6-24 carbon and their salts; amphoteric surface-active agent; and an ester of carboxylic acid insoluble in water e.g. esters of carboxylic acid with 3-30 carbon and alcohol in 1-30 carbon, where at least one of the acid or alcohol is branched, and esters of aromatic acid with 7-30 carbon, where the carboxylic function is directly boned to the aromatic cycle and alcohol with 1-30 carbon, in an aqueous medium and the esters are present at 0.5-10 wt.%. The ratio of anionic surface-active sulfates or sulfonate/anionic carboxylic surface-active agent is 2-12. An independent claim is included for a process of washing and conditioning of the keratinous matters e.g. hair comprising applying the composition to the matters, and rinsing with water after a possible time of break.
FIELD: medicine, biology, immunology, phytotherapy. SUBSTANCE: invention relates to induction of immune response in body with lymphatic system. Biological fluid of body enriched with lymphocytes is irradiated by light in visible spectrum range in the presence of photochemical agent followed by administration of this liquid in body. Aqueous-alcoholic extracts of one or some the following plants are used as a photochemical agent: Siberian cow-parsnip, medicinal garden angelica, burnet saxifrage, meadow saxifrage, medicinal sweet clover, perforated Saint-John's-wort, medicinal matricary, common mullein, sown coriander, fragrant dill, common anise, common thyme, celandine poppy, and birch fungus Inonotus obliquus. Method provides elimination of cytotoxicity with retaining the body immune response. EFFECT: improved inducing method, valuable properties of agent. 2 cl, 1 dwg, 1 ex
Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality.

Influenza can periodically cause worldwide pandemic. For nearly a century, the influenza virus had occurred four large variation, causing three world pandemic. Studies have shown that since 1957, most of those new variants of influenza virus started in China, which is recognized by the world to have high incidence of influenza. At present, trivalent influenza vaccines are widely used in China. They only contain two kinds of type A virus antigens and one type B virus antigen. But since 2000, two kinds of type B strains (Victoria and Yamagata) have caused an alternating cycle in different seasons. Gradually, evolved from the original single lineage of influenza B virus B/Yamagata, two distinct antigenic lineages-B/Victoria and B/Yamagata have alternately dominated or caused a mix of popular lineage. These two lineages have little or nearly no cross-protection. Therefore, trivalent influenza vaccines may not cover the popular strains of influenza B virus, whereas quadrivalent influenza vaccines will help to simultaneously prevent two kinds of type A viruses and two kinds of type B virus.

In order to evaluate safety and tolerance of the quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase I clinical trial is planned to conduct in healthy adults aged from 18 to 49 years in China.
INTRODUCTION: Advances have been made in understanding the aetiology of functional neurological disorder (FND); however, its pathophysiological mechanisms have not been definitively demonstrated. Evidence suggests interacting roles for altered emotional processing and interoception, elevated autonomic arousal, and dissociation, but there is limited evidence demonstrating their causal influence on specific FND symptoms. Our superordinate aim is to elucidate potentially shared and distinct aetiological factors and mechanisms in two common FND subtypes, functional seizures (FS) and functional motor symptoms (FMS).
METHODS: This study has a multimodal, mixed between- and within-groups design. The target sample is 50 individuals with FS, 50 with FMS, 50 clinical controls (anxiety/depression), and 50 healthy controls. Potential aetiological factors (e.g., adverse life events, physical/mental health symptoms, dissociative tendencies, interoceptive insight/sensibility) will be assessed with a detailed medical history interview and self-report questionnaires. A laboratory session will include a neurocognitive battery, psychophysiological testing, cardiac interoception and time estimation tasks and an isometric handgrip task. A subsample will undergo magnetic resonance imaging, including structural, resting-state and task-based scans combined with psychophysiological recording. Remote monitoring with ecological momentary assessment and wearables will measure variability in FND symptoms and their potential predictors/correlates for ≥2 weeks in patients' daily lives. Longitudinal follow-ups at 3, 6, and 12-months will monitor longer-term outcomes in the clinical groups.
DISCUSSION: This study employs multimodal research methods to rigorously examine several putative mechanisms in FND, at subjective/experiential, behavioural, and physiological levels. The study will test causal hypotheses about the role of altered emotional processing, autonomic arousal, dissociation and interoception in the initiation or exacerbation of FND symptoms, directly comparing these processes in FS and FMS to healthy and clinical controls. This is the first study of its kind, with potential to reveal important targets for prevention and treatment of FND in future.
The present invention relates to a composition for skin regeneration, anti-wrinkle, antioxidant, anti-inflammation and skin whitening activities. According to the present invention, bufogenin promotes collagen generation of fibroblasts and thus has effects of regenerating skin and reducing wrinkles. Bufogenin inhibits generation of free radicals and thus has an anti-oxidant effect. Bufogenin also inhibits generation of NO and thus has an anti-inflammatory effect. In addition, bufogenin inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
PURPOSE: To obtain a composition, comprising a specific platinum compound and a nontoxic insert carrier and having anticancer actions on malignant animal tumors. CONSTITUTION: This composition comprises a compound represented by formula I [Pt is in a bivalent state and in the cis steric configuration and is coordinated with A<1> and A<2> ; A<1> and A<2> are each a (substituted)amine or together form a diamine represented by formula II (R<2> and R<3> are each a 1-6C alkyl, etc.); L is a purine, a pyrimidine nucleoside, etc.; X is a monovalent anionic ligand; Y is an anion; (n) is 0 or 1] in combination with a nontoxic inert carrier (e.g. corn starch, sodium carboxymethyl cellulose, ethyl cellulose or acetylcellulose) therein. The compound represented by formula I is administered in a dose required to achieve antitumor effects and within the range of usually about 10-950mg, preferably about 30-450mg based on 1kg body weight of a host animal.
BACKGROUND: This study aimed to examine the evolving trends in the global burden of low back pain (LBP) from 1990 to 2021 and predicted disease burden until 2035.
MATERIALS AND METHODS: LBP-related data were obtained from the Global Health Data Exchange (GHDx) query tool. All estimates and their 95% uncertainty intervals (UIs) were generated using DisMod-MR 2.1, a Bayesian meta-regression tool in Global Burden of Disease, Injury, and Risk Factor Study (GBD) 2021. Data processing and visualization were conducted using The R Programming Language software version 4.3.2 and Joinpoint 4.7.
RESULTS: In 2021, approximately 628.8 million people worldwide were affected by LBP, with approximately 266.9 million new incident cases and age-standardized incidence rate (ASIR) of 3176.6 per 100,000. Compared with 1990, although the ASIR and age-standardized disability-adjusted life years rate (ASDALYsR) decreased, absolute numbers increased significantly. Projections for 2035 reveal a continued decline in ASIR and ASDALYsR for LBP. The LBP burden varied by the sociodemographic index quintile and GBD region, with the highest ASIR and ASDALYsR observed in Central Europe and the greatest decrease in East Asia. Globally, women bear a higher burden of LBP than men, with middle-aged populations experiencing the heaviest burden. Occupational ergonomic factors, high body mass index, and smoking remain the primary risk factors for LBP, with occupational ergonomic factors contributing the most to the overall burden.
CONCLUSION: Despite a projected decline in incidence, the global burden of LBP persists, exhibiting significant regional and gender disparities. To mitigate its future burden, precise and effective prevention and control strategies targeting high-risk factors are imperative.
The objectives are to1. determine the change in dietary fat and PUFA intakes, change in biochemical measures of fatty acid status prospectively from enrollment to 24 months-of-age and 2. to use a nutritional intervention with LCPUFA to address if limiting status of these nutrients impacts growth and development to 24 months-of-age. Primary Endpoints are distributions of developmental tests scores, growth quality and parental reports of child illness. The Bayley Mental and Motor Scales (BSID-III), Peabody Picture Test, Beery Buktenica Developmental Test, Auditory Continuous Performance Test and Test of Attention and Distractibility are used. Growth is assessed as height, weight, and adipose tissue mass and distribution. Child illness is reported by the parent. Secondary endpoints are physiologic measures of blood pressure, heart rate and heart rate variability, and the genetic variables in fatty acid metabolism on fatty acid status and outcome. Blood is collected at enrolment and at 24 months-of-age. Lipids and fatty acids are assessed on plasma and blood cells. Routine, potentially confounding nutrients including iron, vitamin D, choline, folate and B12 are assessed. DNA is extracted from blood cells for genotyping. Dietary intake is assessed using a food frequency questionnaire (FFQ), 3 day food diaries and 24 hour recalls. A parent report illness dairy and questionnaire modified from the International Study of Asthma and Allergies in Childhood is used to assess illness incidence and duration. Descriptive statistics will be used to present subject characteristics, dietary intakes, growth and physiological measures and test results of total fat. Logistic regression, with multivariable-adjusted odds ratios (ORs) of a negative outcome and corresponding 95% CI will be sued to assess the effect of LCPUFA status on development, growth and health outcomes. For all multivariate models, potential confounders will be screened in stepwise fashion, and any covariate with a regression coefficient P-value \< 0.05 (two-sided) will be retained. Performance on tests will be compared as LCPUFA status in the lowest quintile compared to highest quintile of outcome (i.e. the two ends of the distribution differ in LCPUFA status).
Since March 2020, the COVID-19 pandemic has swiftly propagated, triggering a competitive race among medical firms to forge vaccines that thwart the infection. Lebanon initiated its vaccination campaign on February 14, 2021. Despite numerous studies conducted to elucidate the characteristics of immune responses elicited by vaccination, the topic remains unclear. Here, we aimed to track the progression of anti-spike SARS-CoV-2 antibody titers at two-time points (T1: shortly after the second vaccination dose, T2: six months later) within a cohort of 201 adults who received Pfizer-BioNTech (BNT162b2), AstraZeneca, or Sputnik V vaccines in North Lebanon. Blood specimens were obtained from participants, and antibody titers against SARS-CoV-2 were quantified through the Elecsys-Anti-SARS-CoV-2 S assay (Roche Diagnostics, Switzerland). We used univariate analysis and multivariable logistic regression models to predict determinants influencing the decline in immune response and the occurrence of breakthrough infections among vaccinated patients. Among the 201 participants, 141 exhibited unchanging levels of antibody titers between the two sample collections, 55 displayed waning antibody titers, and only five participants demonstrated heightened antibody levels. Notably, age emerged as the sole variable significantly linked to the waning immune response. Moreover, the BNT162b2 vaccine exhibited significantly higher efficacy concerning the occurrence of breakthrough infections when compared with the AstraZeneca vaccine. Overall, our study reflected the immune status of a sample of vaccinated adults in North Lebanon. Further studies on a larger scale are needed at the national level to follow the immune response after vaccination, especially after the addition of the third vaccination dose.
Group 2 will be randomized to the order in which they receive NHP-544C 81 mg, NPH-544C 162.5 mg and identical-appearing placebo for five days. Bradykinin will be given intravenously in graded doses on the fifth day of each treatment period.
This is a prospective, longitudinal cohort study of immunosuppressed patients living in households with and without children to assess the role of household contact with children in the transmission of SARS-CoV-2 to immunocompromised patients. This study will be enrolling both pediatric and adult patients who are immunosuppressed, as well as their household members who agree to participate. Through careful collection of epidemiological data in combination with biological specimens, risk factors for SARS- CoV-2 in immunocompromised patients will be identified. During the initial study visit, informed consent will be obtained, the study questionnaire will be completed and the participant will provide biological specimens including nasal mid-turbinate swabs, saliva and blood. Thereafter, participants will complete at-home saliva collections and questionnaires on a weekly basis for 6 months. If our research-use only SARS-CoV-2 test is positive, participants will be referred immediately to University of California at Los Angeles(UCLA) Health for medical attention and will be followed every 3 days with nasal swabs and saliva samples, and weekly blood specimens and optional rectal swabs or fresh stool collection. Biological specimen and questionnaire follow-up will occur for 6 months for uninfected participants or until the of end of viral shedding and immunologic profiling for patients infected with SARS-CoV-2, whichever is longer. All participants will be followed at 6 months with the same baseline measurements and then participants will be contacted by telephone at 1 year.

The clinical data and biological specimens collected in this initial study will provide will inform and allow future studies of clinical outcomes, viral characteristics, and immune responses to SARS-CoV-2 infection.
In the Familiarization stage (1), the TRMOPL was applied by means of a single evaluator with the aim of knowledge and understanding of the test. After five minutes, step (2) test started. In this step, the test was applied twice, by different evaluators, with an interval of five minutes between applications (inter-rater reliability). Ten minutes after the end of the tests, step (3) retest (intra-rater reliability) was started, following the same procedures as in step 2. The order of the evaluators was randomized through a draw in Excel, the order of randomization of the steps (2) and (3) was the same in order not to influence intra-rater reliability.
Cardiovascular diseases represent the leading global cause of death, typically diagnosed and addressed through electrocardiograms (ECG), which record the heart's electrical activity. In recent years, there has been a notable surge in ECG recordings, driven by the widespread use of wearable devices. However, the limited availability of medical experts to analyze these recordings underscores the necessity for automated ECG analysis using computer-aided methods. In this study, we introduced 3DECG-Net, a deep learning model designed to detect and classify seven distinct heart states through the analysis of data fusion from 12-lead ECG in a multi-label framework. Our model leverages a residual architecture with a multi-head attention mechanism, undergoing training within a five-fold cross-validation scheme. By transforming 12-lead ECG signals into 3D data with the help of Recurrent Plot technique, 3DECG-Net achieves a noteworthy micro F1-score of 80.3 %, surpassing the performance of other state-of-the-art deep learning models developed for this specific task. Also, we present an ECG preprocessing framework to generate compact, high-quality ECG signals for potential application in future studies within this domain. We conduct an explainable AI experiment using Local Interpretable Model-agnostic Explanations (LIME) to elucidate the significance of each lead in accurately diagnosing specific arrhythmias, ensuring the logical processing of ECG data by 3DECG-Net. The findings of this study suggest that the proposed model is trustworthy and has the potential to be used as an effective diagnostic toolset for identifying heart arrhythmias. Its effectiveness can improve the diagnostic process, facilitate early treatment, and enhance overall efficiency in medical settings.
FIELD: medicine. ^ SUBSTANCE: group of inventions concerns medicine, namely to the agents raising action of acoustic energy in a target place during therapy by high-intensive focused ultrasound (HIFU). Application of biocompatible firm substance with nanosized particles, intended for HIFU-therapy, consists in reception of the strengthening agent containing a discrete phase, consisting of biocompatible firm substance with nanosized particles, bagged inside the membrane-creating material; and the continuous phase consisting of water medium, thus a discrete phase is homogeneously dispersed in a continuous phase. The strengthening agent intended for HIFU-therapy, contains a biocompatible firm substance with nanosized particles, the discrete phase homogeneously dispersed in a continuous phase consists of the specified discrete and continuous phases, thus. The way of augmentation of action of acoustic energy in a target place during HIFU-therapy consists in intravenous introduction of the specified strengthening agent in an effective dose by means of continuous and fast intravenous installation or bolus injection to the patient 0-168 hours prior to HIFU-therapy application. ^ EFFECT: rising of efficiency of HIFU-therapy of deeply located and big tumours at certain acoustic power without damage of normal tissues along an acoustic way. ^ 21 cl, 6 ex, 4 tbl
Twenty-five patients will be receive foam sclerosant by an angiographic catheter 4 French. They will be treated with 3% polidocanol foam prepared with a three-way tap and two plastic disposable syringes, according to Tessari's method.
A patient support system for providing improved guidance and/or troubleshooting with respect to a patient support apparatus. A user interface is configured to receive inputs from a user, and an information output device is configured to provide instructions to the user. A controller determines a guidance protocol for the user based on the inputs. The guidance protocol comprises user-performed actions to be performed by the user in response to the instructions provided to the user with the information output device. The guidance protocol may be initiated and/or determined based on a troubleshooting request and/or an uncorrelated sequence of user inputs. At least one of the user-performed actions may be configured to control operational functions of a patient support apparatus. Methods for improving patient care by providing the guidance and/or troubleshooting are also disclosed.
Patients who randomize to the autofill void trial will be allowed to urinate at any time within the first 3 hours after surgery. The amount urinated will be recorded using a commode specimen collection measurer. The PVR will be measured. If PVR \> 100 mL, the void trial will be considered "failed" and a Foley catheter will be replaced.
FIELD: cosmetology. SUBSTANCE: bioactive addition is based on plant extracts and contains the condensed plant extract "Eracond". Composition shows universal prophylaxis action. Proposed composition is used for production of detergent personal hygiene agents using for hair and skin care. EFFECT: enhanced effectiveness of composition. 1 cl